Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation

Table 1 Characteristics of hepatocellular carcinoma patients and univariate assessment of long-term survival after liver transplantation n (%)

Variables	Value	P value
Age (yr)	47.99 ± 9.09	< 0.001
Gender		0.048
Male	204 (91.5)
Female	19 (8.5)
Blood type		0.951
A	66 (29.6)
B	62 (27.8)
O	75 (33.6)
AB	20 (9.0)
Identical	195 (87.4)	0.492
History
Cardiovascular disease	17 (7.6)	0.358
Respiratory disease	3 (1.3)	0.296
Diabetes mellitus	17 (7.6)	0.736
Hepatitis B virus infection	223 (100.0)	0.252
Ascites	144 (64.6)	0.426
Variceal bleeding	25 (11.2)	0.023
Encephalopathy	4 (1.8)	0.799
Treatment related to hepatocellular carcinoma
Hepatectomy	21 (9.4)	0.693
Transplantation	4 (1.8)	< 0.001
TACE	44 (19.7)	0.756
Criteria
Milan		< 0.001
Met	88 (39.5)
Exceeded	135 (60.5)
UCSF		< 0.001
Met	97 (43.5)
Exceeded	126 (56.5)
Shanghai Fudan		< 0.001
Met	116 (52.0)
Exceeded	107 (48.0)
Hangzhou		< 0.001
Met	144 (64.6)
Exceeded	79 (35.4)
MELD score	14.12 ± 7.02	0.086
SCr (μmol/L)	71.41 ± 69.10	0.173
TB (μmol/L)	89.45 ± 174.19	< 0.001
INR	1.42 ± 0.45	0.010
AFP (ng/mL)	5694.77 ± 12584.00	< 0.001
Cold ischemia time (h)	9.21 ± 2.07	0.129
Intraoperative blood loss (IU)	9.24 ± 8.50	0.002
Operation duration (h)	8.29 ± 1.58	0.200
Liver transplantation technique		0.001
Classic	212 (95.1)
Piggyback	11 (4.9)
Biliary reconstruction		< 0.001
Duct-to-duct	221 (99.1)
Roux-en-Y	2 (0.9)
Edmondson grading		0.790
I	8 (3.6)
II	200 (89.7)
III	13 (5.8)
IV	2 (0.9)

MELD: Model for end-stage liver disease; SCr: Serum creatinine; TB: Total bilirubin; INR: International normalized ratio; AFP: Alfa-fetoprotein; UCSF: University of California San Francisco; TACE: Transcatheter arterial chemoembolization.